Newly diagnosed multiple myeloma test of combination therapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 3 trial tests a combination treatment approach for adults with newly diagnosed multiple myeloma, focusing on response and deeper remission. It may help by improving how well the disease is controlled early and measuring results beyond standard tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed multiple myeloma, confirmed by specific blood and bone marrow criteria
- Your overall health/activity level (ECOG) is 0 to 2 (3 is allowed only if from pain)
- You must agree to a special safety program for lenalidomide (RevREMS) and follow its rules
- You must be able to have a bone marrow aspirate and submit it for a clonality test (clonoSEQ)
- Your myeloma must be “standard risk” (not high-risk genetic markers, as defined in the study)
- You must have certain disease measurements and enough blood counts (for example, hemoglobin, neutrophils, and platelets)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares different combinations of medicines for people newly diagnosed with multiple myeloma who cannot safely get a stem cell transplant. It aims to find which drug plan works best and is tolerable for people with “frail” or “intermediate fit” health.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This trial tests a combination of two antibody drugs (elotuzumab and daratumumab) plus an oral pill (iberdomide) and a steroid (dexamethasone) for people whose multiple myeloma has come back after treatment. The goal is to see if this new mix works better than what's already available.
Hear when a new Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.